Home  /  Resource Library  /  Fixed-duration glofitamab monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Brutons tyrosine kinase inhibitor (BTKi) exposure: Updated data after a 3.5-year follow-up

Fixed-duration glofitamab monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Brutons tyrosine kinase inhibitor (BTKi) exposure: Updated data after a 3.5-year follow-up

ASCO 2026